UroGen Pharma Ltd. (URGN) Operating Margin
- Operating margin · 12 months: Value -35.32%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -35.32% | Operating income / revenue. Period ending 2026-06-30. $-66.65M ÷ $188.73M × 100 ≈ -35.32% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -66.65M USD | Operating Income (Loss) |
| Revenue | 188.73M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 61.26M USD | Research and Development Expense |
| Selling, general and administration | 176.85M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-66.65M | $188.73M | (m) | $61.26M | $176.85M | -35.32% |
| 2026-03-31 | $-108.21M | $140.49M | (m) | $62.83M | $171.62M | -77.02% |
| 2025-12-31 | $-124.86M | $109.79M | (m) | $67.11M | $155.10M | -113.73% |
| 2025-09-30 | $-133.41M | $96.52M | (m) | $67.69M | $150.61M | -138.22% |
| 2025-06-30 | $-123.56M | $94.24M | (m) | $65.03M | $141.97M | -131.12% |
| 2025-03-31 | $-107.96M | $91.87M | (m) | $61.52M | $128.82M | -117.51% |
| 2024-12-31 | $-96.78M | $90.40M | (m) | $57.15M | $121.15M | -107.06% |
| 2024-09-30 | $-83.73M | $89.36M | (m) | $53.55M | $110.85M | -93.70% |
| 2024-06-30 | $-79.69M | $85.01M | (m) | $52.43M | $103.66M | -93.74% |
| 2024-03-31 | $-69.23M | $84.30M | (m) | $48.61M | $96.10M | -82.12% |
| 2023-12-31 | $-65.54M | $82.71M | (m) | $45.61M | $93.27M | -79.23% |
| 2023-09-30 | $-71.21M | $77.28M | (m) | $48.79M | $90.36M | -92.15% |
| 2023-06-30 | $-75.80M | $72.52M | (m) | $51.65M | $87.67M | -104.52% |
| 2023-03-31 | $-79.13M | $67.98M | (m) | $52.71M | $86.01M | -116.39% |
| 2022-12-31 | $-79.04M | $64.36M | (m) | $52.91M | $82.84M | -122.82% |
| 2022-09-30 | $-78.67M | $62.44M | (m) | $51.51M | $82.62M | -126.00% |
| 2022-06-30 | $-84.03M | $57.69M | (m) | $50.34M | $85.17M | -145.65% |
| 2022-03-31 | $-88.14M | $54.12M | (m) | $49.83M | $86.65M | -162.85% |
| 2021-12-31 | $-92.29M | $48.04M | (m) | $47.64M | $87.53M | -192.11% |
| 2021-09-30 | $-99.63M | $39.83M | (m) | $46.97M | $88.28M | -250.12% |
| 2021-06-30 | $-105.31M | $31.94M | (m) | $45.25M | $88.72M | -329.69% |
| 2021-03-31 | $-114.29M | $19.28M | (m) | $41.23M | $90.44M | -592.68% |
| 2020-12-31 | $-126.74M | $11.80M | (m) | $47.31M | $90.22M | -1074.15% |
| 2020-09-30 | $-139.32M | $3.83M | (m) | $55.00M | (m) | -3634.86% |
| 2020-06-30 | $-133.65M | $372.00K | (m) | $54.27M | (m) | -35928.23% |
| 2020-03-31 | $-125.61M | (m) | (m) | $56.16M | (m) | (m) |
| 2019-12-31 | $-109.48M | $18.00K | (m) | $49.30M | (m) | -608211.11% |
| 2019-09-30 | $-93.66M | $18.00K | (m) | (m) | (m) | -520311.11% |
| 2019-06-30 | $-91.29M | $301.00K | (m) | (m) | (m) | -30329.57% |
| 2019-03-31 | $-85.97M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-77.18M | $1.13M | (m) | (m) | (m) | -6842.20% |
| 2018-09-30 | $-63.32M | $1.46M | (m) | (m) | (m) | -4351.96% |
| 2018-06-30 | $-42.53M | $8.98M | (m) | (m) | (m) | -473.45% |
| 2018-03-31 | $-30.05M | $8.62M | (m) | (m) | (m) | -348.63% |
| 2017-12-31 | $-19.95M | $8.16M | (m) | (m) | (m) | -244.55% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $798.00K | $17.53M | (m) | (m) | (m) | 4.55% |
| 2015-12-31 | $-12.41M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |